PT  - JOURNAL ARTICLE
AU  - Love, Jay
AU  - Keegan, Lindsay T.
AU  - Angulo, Frederick J.
AU  - McLaughlin, John
AU  - Shea, Kimberly M.
AU  - Swerdlow, David L.
AU  - Samore, Matthew H.
AU  - Toth, Damon J.A.
TI  - Continued need for non-pharmaceutical interventions after COVID-19 vaccination in long-term-care facilities
AID  - 10.1101/2021.01.06.21249339
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.06.21249339
4099  - http://medrxiv.org/content/early/2021/01/06/2021.01.06.21249339.short
4100  - http://medrxiv.org/content/early/2021/01/06/2021.01.06.21249339.full
AB  - Long-term care facilities (LTCFs) bear disproportionate burden of COVID-19 and are prioritized for vaccine deployment. LTCF outbreaks could continue occurring during vaccine rollout due to incomplete population coverage, and the effect of vaccines on viral transmission are currently unknown. Declining adherence to non-pharmaceutical interventions (NPIs) against within-facility transmission could therefore limit the effectiveness of vaccination. We built a stochastic model to simulate outbreaks in LTCF populations with differing vaccination coverage and NPI adherence to evaluate their interacting effects. Vaccination combined with strong NPI adherence produced the least morbidity and mortality. Healthcare worker vaccination improved outcomes in unvaccinated LTCF residents but was less impactful with declining NPI adherence. To prevent further illness and deaths, there is a continued need for NPIs in LTCFs during vaccine rollout.Competing Interest StatementDrs. Angulo, Mclaughlin, Shea, and Swerdlow reported being employed by Pfizer Vaccines. This work was supported by Pfizer. Pfizer Inc. reviewed this manuscript and approved the decision to submit the manuscript for publication.Funding StatementFunding was provided by Pfizer, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval needed - modeling and simulation only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and model code will be made publicly available upon publication or request.